Old chemo drug gets new partner in fight against lung cancer
NCT ID NCT03801304
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase II trial tests whether a low-dose, frequent schedule of the chemotherapy drug vinorelbine, taken orally, can boost the effects of the immunotherapy atezolizumab in people with stage IV non-small cell lung cancer. The study enrolls adults whose cancer has progressed after initial treatment and who do not have certain genetic mutations. The goal is to see if this combination can delay disease progression or death better than current second-line options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vinorelbine and atezolizumab
What this could lead to
If successful, this combination could offer a new second-line treatment option for advanced lung cancer patients who have limited choices.
What could go wrong
This is an early-phase trial with only 80 participants, so results may not apply broadly. The combination may cause side effects or fail to improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Aix en Provence
Aix-en-Provence, France, France
-
CH MEAUX
Meaux, France, France
-
CH Pringy
Pringy, France, France
-
CH Quimper
Quimper, France, France
-
CH Saint-Brieuc
Saint-Brieuc, France, France
-
CH de Créteil
Créteil, France, 94010, France
-
CHRU de Brest - Hôpital Morvan
Brest, France, 29609, France
-
CHU Rouen
Rouen, France, France
-
CHU de Limoges - Hôpital DUPUYTREN
Limoges, France, 87042, France
-
CHU de Rennes
Rennes, France, 35033, France
-
CLCC Caen
Caen, France, France
-
Ch La Roche Sur Yon
La Roche-sur-Yon, France, 85000, France
-
Hia Saint Anne
Toulon, France, 83041, France